title: High-risk characteristics of fellow eyes of patients with unilateral neovascular age-related macular degeneration.
abstract: OBJECTIVE
  This study aimed to determine whether clinical tests of ocular function and macular appearance independently can help to predict which patients with unilateral neovascular age-related macular degeneration (AMD) will have a choroidal neovascular membrane (CNVM) develop in their fellow eye.
  
  
  METHODS
  The study design was a prospective cohort study.
  
  
  METHODS
  One hundred twenty-seven patients with unilateral neovascular AMD observed for up to 4.5 years participated.
  
  
  METHODS
  Functional measurements included visual acuity, macular visual field, glare recovery time, and foveal electroretinogram amplitude and implicit time.
  
  
  METHODS
  The age-adjusted proportion of patients having a CNVM develop over follow-up assessed by the Cox proportional hazards model with stepwise selection was measured.
  
  
  RESULTS
  On average, 8.8% of patients had a CNVM develop each year. Independent risk factors for the fellow eye were its glare recovery time in minutes (relative risk = 1.30, confidence interval = 1.10-1.54, P = 0.003) and its extent of visible macular abnormalities on a four-point scale (relative risk = 1.62, confidence interval = 1.06-2.59, P = 0.03). Of the fellow eyes that converted, the interval to have a CNVM develop was inversely related to the foveal electroretinogram implicit time.
  
  
  CONCLUSIONS
  A slower recovery from glare and more extensive funduscopic changes appear to be independent risk factors for the development of a CNVM in the fellow eyes of patients with unilateral neovascular AMD. A slower foveal electroretinogram implicit time may be a sign of early stage CNVM development, perhaps because of outer retinal ischemia. These results have clinical management implications, particularly for those patients at high risk of having a potentially treatable form of AMD develop.
authors.affiliation: Berman-Gund Laboratory for the Study of Retinal Degenerations, Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston 02114, USA.
authors.forename: M A
authors.initials: MA
authors.lastname: Sandberg
authors.forename: A
authors.initials: A
authors.lastname: Weiner
authors.forename: S
authors.initials: S
authors.lastname: Miller
authors.forename: A R
authors.initials: AR
authors.lastname: Gaudio
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002829:Choroid / Q000098:blood supply*; D015331:Cohort Studies; D004596:Electroretinography; D005260:Female; D005500:Follow-Up Studies; D005654:Fundus Oculi; D019466:Glare; D006801:Humans; D008268:Macular Degeneration / Q000150:complications* / Q000175:diagnosis* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000150:complications* / Q000175:diagnosis* / Q000503:physiopathology; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012160:Retina / Q000502:physiology; D012307:Risk Factors; D014792:Visual Acuity / Q000502:physiology; D014794:Visual Fields / Q000502:physiology